Peptide record

TPDB19214

Antibacterial Anticancer Antiviral Toxicity standard
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB19214
Antibacterial Anticancer Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia dbAMP 3.0 DRAMP DRAVP 2.0
standard
No
A 9-aa standard-residue multi-activity (Antibacterial, Anticancer, Antiviral, and other sources) peptide sequence curated from Peptipedia, dbAMP 3.0, DRAMP, and other sources, with an available 3D structural model.
Sequence
FLHFLHHLF
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C63H83N15O10
ARNDCEQGIKMPSTWYV
HLF
1210.45
8.09
3
0
6
+0
-1.08
1.133
130.00
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
3
H
0
I
3
L
0
K
0
M
3
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 3 I: 0 L: 3 K: 0 M: 0 F: 3 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
9 reviewed residue count
C63H83N15O10 sequence-only estimate (linear, free termini)
1210.45 sequence-only estimate (linear, free termini)
8.09 sequence-only estimate (linear, free termini)
+0 sequence-only estimate (linear, free termini)
-1.08 sequence-only estimate (linear, free termini)
1.133 sequence-only estimate (linear, free termini)
Evidence Records 4 records
Evidence 1 Activity

Activity

Antibacterial

Source & Reference

DRAMP

Other

inhibit hepatitis C virus (HCV) infection (EC50 0.85 ug/ml).
Evidence 2 Activity

Activity

Antiviral

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
dbAMP 3.0 classified under the Anti-viral function class.
inhibit hepatitis C virus (HCV) infection (EC50 0.85 ug/ml).
Evidence 3 Activity

Activity

50% Hemolysis
Toxicity
416.4 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 416.4 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. | Biomaterials | 2013
Evidence 4 Activity

Activity

HC50
Toxicity
416.4 µg/mL
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.23415044] HC50 = 416.4 µg/ml against human red blood cells. | Cytotoxicity: [Ref.23415044] CC50>500 µg/ml against Huh7.5.1 cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Biomaterials. 2013 Apr 34(13):3511-22.